AstraZeneca AB, Gothenburg, Sweden 8th-9th June 2016
York, UK, 11 May 2016: ELRIG (European Laboratory Research & Innovation Group) today announced the final programme for the second Recombinant Protein Technology (RPT) conference, a series that focusses on the latest technological advances in the design and production of recombinant proteins as biotherapeutics and in drug discovery.
Building on the success of the inaugural event, the meeting is expected to attract over 240 delegates and 30 delegates to the AstraZeneca AB site at Gothenburg in Sweden. The full programme, including all speakers and sessions, as well as free delegate registration, can be found at: http://elrig.org/portfolio/recombinant-protein-technology-2016-elrigrpt16/.
The two-day conference will feature world class speakers and will bring together researchers from top academic and industrial laboratories to discuss the latest advances in recombinant protein technology. Themes will run across three tracks and address the current understanding of molecular events that determine quality and productivity and the use of specific cell hosts for particular types of protein product.
In particular, the conference will focus on the biology of existing host cells and how both host cell and desired proteins may be engineered to generate new systems for enhanced product expression. Presentations will cover developments in areas crucial to drug discovery including host cell factories, genome editing, protein engineering and novel scaffolds.
In addition to a schedule of scientific presentations the event will feature poster sessions, a Snapshot forum where five companies will showcase their technology, and a vendor exhibition area as well as offering significant opportunities for networking. .
York, UK, 11 May 2016: ELRIG (European Laboratory Research & Innovation Group) today announced the final programme for the second Recombinant Protein Technology (RPT) conference, a series that focusses on the latest technological advances in the design and production of recombinant proteins as biotherapeutics and in drug discovery.
Building on the success of the inaugural event, the meeting is expected to attract over 240 delegates and 30 delegates to the AstraZeneca AB site at Gothenburg in Sweden. The full programme, including all speakers and sessions, as well as free delegate registration, can be found at: http://elrig.org/portfolio/recombinant-protein-technology-2016-elrigrpt16/.
The two-day conference will feature world class speakers and will bring together researchers from top academic and industrial laboratories to discuss the latest advances in recombinant protein technology. Themes will run across three tracks and address the current understanding of molecular events that determine quality and productivity and the use of specific cell hosts for particular types of protein product.
In particular, the conference will focus on the biology of existing host cells and how both host cell and desired proteins may be engineered to generate new systems for enhanced product expression. Presentations will cover developments in areas crucial to drug discovery including host cell factories, genome editing, protein engineering and novel scaffolds.
In addition to a schedule of scientific presentations the event will feature poster sessions, a Snapshot forum where five companies will showcase their technology, and a vendor exhibition area as well as offering significant opportunities for networking. .
